Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer

Raquibul Hannan, Huagang Zhang, Anu Wallecha, Reshma Singh, Laibin Liu, Patrice Cohen, Alan Alfieri, John Rothman, Chandan Guha

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Radiation therapy (RT) is an integral part of prostate cancer treatment across all stages and risk groups. Immunotherapy using a live, attenuated, Listeria monocytogenes- based vaccines have been shown previously to be highly efficient in stimulating anti-tumor responses to impact on the growth of established tumors in different tumor models. Here, we evaluated the combination of RT and immunotherapy using Listeria monocytogenes-based vaccine (ADXS31-142) in a mouse model of prostate cancer. Mice bearing PSA-expressing TPSA23 tumor were divided to 5 groups receiving no treatment, ADXS31-142, RT (10 Gy), control Listeria vector and combination of ADXS31-142 and RT. Tumor growth curve was generated by measuring the tumor volume biweekly. Tumor tissue, spleen, and sera were harvested from each group for IFN-γ ELISpot, intracellular cytokine assay, tetramer analysis, and immunofluorescence staining. There was a significant tumor growth delay in mice that received combined ADXS31-142 andRTtreatment as compared with mice of other cohorts and this combined treatment causes complete regression of their established tumors in 60 % of the mice. ELISpot and immunohistochemistry of CD8+ cytotoxic T Lymphocytes (CTL) showed a significant increase in IFN-γ production in mice with combined treatment. Tetramer analysis showed a fourfold and a greater than 16-fold increase in PSA-specific CTLs in animals receiving ADXS31-142 alone and combination treatment, respectively. A similar increase in infiltration of CTLs was observed in the tumor tissues. Combination therapy with RT and Listeria PSA vaccine causes significant tumor regression by augmenting PSAspecific immune response and it could serve as a potential treatment regimen for prostate cancer.

Original languageEnglish (US)
Pages (from-to)2227-2238
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume61
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Active Immunotherapy
Listeria monocytogenes
Immunotherapy
Prostatic Neoplasms
Radiotherapy
Neoplasms
Therapeutics
Listeria
Vaccines
Growth
Cytotoxic T-Lymphocytes
Tumor Burden
Fluorescent Antibody Technique
Spleen
Immunohistochemistry
Staining and Labeling
Cytokines

Keywords

  • Immunotherapy
  • Listeria PSA vaccine
  • Prostate cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. / Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 12, 12.2012, p. 2227-2238.

Research output: Contribution to journalArticle

Hannan, Raquibul ; Zhang, Huagang ; Wallecha, Anu ; Singh, Reshma ; Liu, Laibin ; Cohen, Patrice ; Alfieri, Alan ; Rothman, John ; Guha, Chandan. / Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. In: Cancer Immunology, Immunotherapy. 2012 ; Vol. 61, No. 12. pp. 2227-2238.
@article{f330e44955804fe785a5edcc19992c4f,
title = "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer",
abstract = "Radiation therapy (RT) is an integral part of prostate cancer treatment across all stages and risk groups. Immunotherapy using a live, attenuated, Listeria monocytogenes- based vaccines have been shown previously to be highly efficient in stimulating anti-tumor responses to impact on the growth of established tumors in different tumor models. Here, we evaluated the combination of RT and immunotherapy using Listeria monocytogenes-based vaccine (ADXS31-142) in a mouse model of prostate cancer. Mice bearing PSA-expressing TPSA23 tumor were divided to 5 groups receiving no treatment, ADXS31-142, RT (10 Gy), control Listeria vector and combination of ADXS31-142 and RT. Tumor growth curve was generated by measuring the tumor volume biweekly. Tumor tissue, spleen, and sera were harvested from each group for IFN-γ ELISpot, intracellular cytokine assay, tetramer analysis, and immunofluorescence staining. There was a significant tumor growth delay in mice that received combined ADXS31-142 andRTtreatment as compared with mice of other cohorts and this combined treatment causes complete regression of their established tumors in 60 {\%} of the mice. ELISpot and immunohistochemistry of CD8+ cytotoxic T Lymphocytes (CTL) showed a significant increase in IFN-γ production in mice with combined treatment. Tetramer analysis showed a fourfold and a greater than 16-fold increase in PSA-specific CTLs in animals receiving ADXS31-142 alone and combination treatment, respectively. A similar increase in infiltration of CTLs was observed in the tumor tissues. Combination therapy with RT and Listeria PSA vaccine causes significant tumor regression by augmenting PSAspecific immune response and it could serve as a potential treatment regimen for prostate cancer.",
keywords = "Immunotherapy, Listeria PSA vaccine, Prostate cancer, Radiation therapy",
author = "Raquibul Hannan and Huagang Zhang and Anu Wallecha and Reshma Singh and Laibin Liu and Patrice Cohen and Alan Alfieri and John Rothman and Chandan Guha",
year = "2012",
month = "12",
doi = "10.1007/s00262-012-1257-x",
language = "English (US)",
volume = "61",
pages = "2227--2238",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",

}

TY - JOUR

T1 - Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer

AU - Hannan, Raquibul

AU - Zhang, Huagang

AU - Wallecha, Anu

AU - Singh, Reshma

AU - Liu, Laibin

AU - Cohen, Patrice

AU - Alfieri, Alan

AU - Rothman, John

AU - Guha, Chandan

PY - 2012/12

Y1 - 2012/12

N2 - Radiation therapy (RT) is an integral part of prostate cancer treatment across all stages and risk groups. Immunotherapy using a live, attenuated, Listeria monocytogenes- based vaccines have been shown previously to be highly efficient in stimulating anti-tumor responses to impact on the growth of established tumors in different tumor models. Here, we evaluated the combination of RT and immunotherapy using Listeria monocytogenes-based vaccine (ADXS31-142) in a mouse model of prostate cancer. Mice bearing PSA-expressing TPSA23 tumor were divided to 5 groups receiving no treatment, ADXS31-142, RT (10 Gy), control Listeria vector and combination of ADXS31-142 and RT. Tumor growth curve was generated by measuring the tumor volume biweekly. Tumor tissue, spleen, and sera were harvested from each group for IFN-γ ELISpot, intracellular cytokine assay, tetramer analysis, and immunofluorescence staining. There was a significant tumor growth delay in mice that received combined ADXS31-142 andRTtreatment as compared with mice of other cohorts and this combined treatment causes complete regression of their established tumors in 60 % of the mice. ELISpot and immunohistochemistry of CD8+ cytotoxic T Lymphocytes (CTL) showed a significant increase in IFN-γ production in mice with combined treatment. Tetramer analysis showed a fourfold and a greater than 16-fold increase in PSA-specific CTLs in animals receiving ADXS31-142 alone and combination treatment, respectively. A similar increase in infiltration of CTLs was observed in the tumor tissues. Combination therapy with RT and Listeria PSA vaccine causes significant tumor regression by augmenting PSAspecific immune response and it could serve as a potential treatment regimen for prostate cancer.

AB - Radiation therapy (RT) is an integral part of prostate cancer treatment across all stages and risk groups. Immunotherapy using a live, attenuated, Listeria monocytogenes- based vaccines have been shown previously to be highly efficient in stimulating anti-tumor responses to impact on the growth of established tumors in different tumor models. Here, we evaluated the combination of RT and immunotherapy using Listeria monocytogenes-based vaccine (ADXS31-142) in a mouse model of prostate cancer. Mice bearing PSA-expressing TPSA23 tumor were divided to 5 groups receiving no treatment, ADXS31-142, RT (10 Gy), control Listeria vector and combination of ADXS31-142 and RT. Tumor growth curve was generated by measuring the tumor volume biweekly. Tumor tissue, spleen, and sera were harvested from each group for IFN-γ ELISpot, intracellular cytokine assay, tetramer analysis, and immunofluorescence staining. There was a significant tumor growth delay in mice that received combined ADXS31-142 andRTtreatment as compared with mice of other cohorts and this combined treatment causes complete regression of their established tumors in 60 % of the mice. ELISpot and immunohistochemistry of CD8+ cytotoxic T Lymphocytes (CTL) showed a significant increase in IFN-γ production in mice with combined treatment. Tetramer analysis showed a fourfold and a greater than 16-fold increase in PSA-specific CTLs in animals receiving ADXS31-142 alone and combination treatment, respectively. A similar increase in infiltration of CTLs was observed in the tumor tissues. Combination therapy with RT and Listeria PSA vaccine causes significant tumor regression by augmenting PSAspecific immune response and it could serve as a potential treatment regimen for prostate cancer.

KW - Immunotherapy

KW - Listeria PSA vaccine

KW - Prostate cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84870996402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870996402&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1257-x

DO - 10.1007/s00262-012-1257-x

M3 - Article

VL - 61

SP - 2227

EP - 2238

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 12

ER -